Investigational drug · Phase 3
KH607
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Major Depressive Disorder (MDD), Postpartum Depressive Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
6
Any phase or sponsor naming "KH607"
First trial start
2025
Mar 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KH607", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder (MDD)
- Postpartum Depressive Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "KH607" as an intervention, largest first.
- Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive DisorderPivotal-lookingNot yet recruiting
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT07741331 · 326 participants (planned) · Start Jul 2026 · Primary completion Dec 2027
Drug: KH607 tablets; Vortioxetine Hydrobromide Tablets and 1 more · For: Major Depressive Disorder (MDD)
- A Study of KH607 as Monotherpy in Adults Participants With Major Depressive DisorderPivotal-lookingNot yet recruiting
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT07741240 · 232 participants (planned) · Start Jul 2026 · Primary completion Dec 2027
Drug: KH607 tablets; placebo and 1 more · For: Major Depressive Disorder (MDD)
- A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive DisorderPivotal-lookingCompleted
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT07101120 · 126 participants · Start Mar 19, 2025 · Primary completion Feb 9, 2026
Drug: KH607 tablets; placebo and 2 more · For: Major Depressive Disorder (MDD)
Sites: Beijing, China
- Phase 1 Study of KH607 TabletsStatus unknown
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT06393803 · 88 participants (planned) · Start Oct 21, 2023 · Primary completion Oct 30, 2024
Drug: 2mg KH607 tablets; 5mg KH607 tablets and 6 more · For: Healthy
Sites: Beijing, China
- A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum DepressionCompleted
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT07096791 · 72 participants · Start Sep 2, 2025 · Primary completion Apr 24, 2026
Drug: KH607 tablet; placebo · For: Postpartum Depressive Disorder
Sites: Beijing, China
- A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of KH607 in Healthy Chinese ParticipantsNot yet recruiting
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Industry
NCT07634874 · 16 participants (planned) · Start Jun 2026 · Primary completion Jul 2026
Drug: KH607; KH607 · For: Food Effect of KH607 in Chinese Health Participants
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Major Depressive Disorder (MDD)
- CYB003Phase 33 trials
Cybin IRL Limited · Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults
- Bupropion Sustained-ReleasePhase 31 trial
CSPC Ouyi Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)
- DT-101Phase 22 trials
Draig Therapeutics Ltd · Major Depressive Disorder (MDD)
- SPT-300LYT-300, GlyphAlloPhase 22 trials
Seaport Therapeutics · Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
- ACP-211Phase 21 trial
ACADIA Pharmaceuticals Inc. · Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
- NH102Phase 21 trial
Jiangsu Nhwa Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)
- SPN-821Phase 21 trial
Supernus Pharmaceuticals, Inc. · Major Depressive Disorder (MDD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.